The BAFF- and a proliferation-inducing ligand (APRIL)-neutralizing atacicept also reduces B cell counts in patients with SLE, underscoring the versatility of options in modulating this pathway [29, 38]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.